Moreover, adult T-ALL patients with IL-7R pathway mutations (which associate with Notch pathway mutations) are slow-responders that benefit from post-induction chemotherapy but not from hematopoietic stem cell transplantation [59]. The gene discussed is IL7R; the disease is acute lymphoblastic leukemia.